Inactive Instrument

American CryoStem Corporation

Equities

CRYO

US0253001046

Biotechnology & Medical Research

American CryoStem Corporation Reports Earnings Results for the First Quarter Ended December 31, 2021

February 22, 2022 at 08:52 pm

American CryoStem Corporation reported earnings results for the first quarter ended December 31, 2021. For the first quarter, the company reported revenue was USD 0.061185 million compared to USD 0.1266 million a year ago. Net loss was USD 0.380755 million compared to USD 0.046034 million a year ago.

Basic loss per share from continuing operations was USD 0.007 compared to USD 0.001 a year ago.

Latest news about American CryoStem Corporation

American CryoStem Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022	22/08/22	CI
American CryoStem Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022	23/05/22	CI
American CryoStem Corporation Reports Earnings Results for the First Quarter Ended December 31, 2021	22/02/22	CI
American CryoStem Corporation Reports Earnings Results for the Full Year Ended September 30, 2021	13/01/22	CI
American CryoStem Corporation Auditor Raises 'Going Concern' Doubt	12/01/22	CI
American Cryostem Corporation Reports Earnings Results for the Third Quarter Ended June 30, 2021	23/08/21	CI
American Cryostem Corporation Reports Earnings Results for the Second Quarter Ended March 31, 2021	17/05/21	CI
American Cryostem Corporation Reports Earnings Results for the Full Year Ended September 30, 2020	08/01/21	CI
American Cryostem Corporation Reports Earnings Results for the Third Quarter Ended June 30, 2020	19/08/20	CI
American Cryostem Corporation Reports Earnings Results for the Second Quarter Ended March 31, 2020	20/05/20	CI
American Cryostem Corporation Reports Earnings Results for the First Quarter Ended December 31, 2019	19/02/20	CI
American Cryostem Corporation Reports Earnings Results for the Full Year Ended September 30, 2019	14/01/20	CI
American Cryostem Corporation Reports Earnings Results for the Third Quarter Ended June 30, 2019	19/08/19	CI
American Cryostem Corporation Reports Earnings Results for the Second Quarter Ended March 31, 2019	20/05/19	CI
American CryoStem Corporation Completes Cooperative Framework Agreement to Expand Market Presence in Japan	20/03/19	CI
American Cryostem Corporation Reports Earnings Results for the First Quarter Ended December 31, 2018	19/02/19	CI
American CryoStem Corporation Enters into Agreement to License its Patented Adipose Tissue and Stem Cell Technologies in Thailand	05/04/18	CI
American CryoStem Corporation Secures Major Contract in Mainland China	25/09/17	CI
American Cryostem Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2017	22/08/17	CI
American Cryostem Corporation Reports Revenue Results for the Year Ended September 30, 2016	03/01/17	CI
American CryoStem Corporation Expands with the Opening of New Lab Facility in Princeton, NJ	06/04/16	CI
American Cryostem Corporation Auditor Raises 'Going Concern' Doubt	12/01/16	CI
American Cryostem Corporation Signs Licensing Agreement with Cell Source	22/07/15	CI
American Cryostem Corporation acquired certain assets of BioLife Cell Bank, Inc.	20/04/15	CI
American Cryostem Corporation Auditor Raises 'Going Concern' Doubt	19/01/15	CI

Chart American CryoStem Corporation

Duration

Period

More charts

Company Profile

American CryoStem Corporation is a biotechnology company. The Company has developed adipose tissue-derived technologies (Adult Stem Cells) for the fields of regenerative and personalized medicine. Its technologies are the basis for the chemistry, manufacturing, and controls (cGMP Manufacturing) of its ATCell autologous cellular therapy product for use in clinical investigations for biologic license applications with the United States Food and Drug Administration (FDA). The Company has developed and refined its pipeline around its cellular product, ATCell, for clinical therapeutic use. The Companyâs ATCELL cell lines are cultured in its patented ACSelerate cell culture media. Its CELLECT service is the required platform for the collection and transportation of live adipose tissue samples to its processing facility. Its ACSelerate cell culture media products are manufactured using patented cell culture media for growing human stromal cells. The Company also includes ATGRAFT services.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+29.03%	49.18B
IQVIA HOLDINGS INC.	-0.10%	42.11B
LONZA GROUP AG	+43.45%	40.37B
CELLTRION, INC.	-5.26%	28.85B
ICON PUBLIC LIMITED COMPANY	+11.48%	26.09B
ALNYLAM PHARMACEUTICALS, INC.	-22.74%	18.71B
BIO-TECHNE CORPORATION	+9.06%	13.26B
MEDPACE HOLDINGS, INC.	+30.01%	12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.51%	11.99B

Other Biotechnology & Medical Research